Abvc Biopharma (ABVC) Deferred Taxes (2018 - 2023)
Abvc Biopharma's (ABVC) quarterly Deferred Taxes came in at $151387.0 in Q4 2023, down 83.11% YoY from $896049.0 in Q4 2022, and up 228.93% on a QoQ basis from -$117414.0 in Q3 2023.
Abvc Biopharma (ABVC) Deferred Taxes (2018 - 2023) Analysis & Trends
Abvc Biopharma (ABVC) has 6 years of Deferred Taxes data on file, last reported at $151387.0 in Q4 2023.
- Quarterly Deferred Taxes fell 83.11% year-over-year to $151387.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $1.1 million (up 23.6% YoY) and the FY2023 annual result came in at $115668.0, down 86.62% from the prior year.
- Deferred Taxes climbed to $151387.0 in Q4 2023, from -$117414.0 in the prior quarter.
- In the past five years, Deferred Taxes ranged from a high of $896049.0 in Q4 2022 to a low of -$117414.0 in Q3 2023.
- A 5-year average of $83475.4 and a median of -$40568.0 in 2020 frame the typical range for Deferred Taxes.
- Annual changes were most pronounced in 2020 — Deferred Taxes sank 207.99% — and 2021, when it soared 756.76%.
- Tracing ABVC's Deferred Taxes over 5 years: stood at -$28054.0 in 2019, then slumped by 207.99% to -$86404.0 in 2020, then soared by 756.76% to $567468.0 in 2021, then jumped by 57.9% to $896049.0 in 2022, then slumped by 83.11% to $151387.0 in 2023.
- The last three Deferred Taxes figures came in at $151387.0 (Q4 2023), -$117414.0 (Q3 2023), and $896049.0 (Q4 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -69.70 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 194.40 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 2.66 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | - |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Abvc Biopharma | 23.34 Mn | 23.34 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 151,387.00 |
| Sep 30, 2023 | -117,414.00 |
| Dec 31, 2022 | 896,049.00 |
| Sep 30, 2022 | 138,871.00 |
| Jun 30, 2022 | -83,251.00 |
| Mar 31, 2022 | -86,867.00 |
| Dec 31, 2021 | 567,468.00 |
| Sep 30, 2021 | 132,331.00 |
| Mar 31, 2021 | 124,400.00 |
| Dec 31, 2020 | -86,404.00 |
| Sep 30, 2020 | -44,735.00 |
| Jun 30, 2020 | -51,494.00 |
| Mar 31, 2020 | -40,568.00 |
| Dec 31, 2019 | -28,054.00 |
| Sep 30, 2019 | 48,555.00 |
| Jun 30, 2019 | -53,165.00 |
| Mar 31, 2019 | -48,028.00 |
| Dec 31, 2018 | -124,855.00 |
| Sep 30, 2018 | -69,075.00 |
| Jun 30, 2018 | -76,885.00 |